venBio Partners L.P.
data from 31/12/2018
Capitalization
Portfolio size
Portfolio performance
Portfolio performance %
Performance compared to S&P 500 (%)
Stock in venBio Partners L.P.
| Date | Ticket | Name | Weight | Capitalization | Share number | First added | Performance ($) | Performance (%) |
|---|---|---|---|---|---|---|---|---|
| 2018/12/31 | Apellis Pharmaceuticals, Inc | 62.01% | 23.611 M $ | 1790102 | 2017/12/31 | -8.217 M $ | -25.82 % | |
| 2018/12/31 | VRNA | Verona Pharma PLC | 22.18% | 8.444 M $ | 875000 | 2017/12/31 | -2.712 M $ | -24.78 % |
| 2018/12/31 | Menlo Therapeutics Inc. | 15.82% | 6.022 M $ | 1461552 | 2018/03/31 | -8.375 M $ | -58.17 % |